Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry

Consistencies and discrepancies in corporate social responsibility reporting in the... This paper aims to examine the consistencies and discrepancies in corporate social responsibility (CSR) reporting by analyzing the CSR reports of pharmaceutical companies. Despite the major role pharmaceutical companies play in the CSR field, our knowledge of the extent to which their disclosures provide comprehensive, material, credible and accurate information on their actual performances is limited because of a lack of sufficient literature on the CSR reporting practices of pharmaceutical companies.Design/methodology/approachThe authors present a literature review that serves as the basis to develop the two key research questions: Do pharmaceutical companies publish comprehensive CSR reports? Are company reports that cover more material issues more comprehensive? Using the information on material CSR topics provided by the Sustainability Accounting Standards Board (SASB) and CSR reporting quality scores by the CSR-Sustainability Monitor®, the authors analyzed the CSR reports of the world’s 15 leading pharmaceutical companies. A total of 11 material topics from SASB were mapped onto the corresponding contextual elements in the CSR-Sustainability Monitor. The Monitor evaluates CSR reports published by the world’s largest companies in terms of the degree of transparency and external verification of reporting.FindingsThe analyses revealed that while the pharmaceutical industry outperforms other industries in terms of the overall comprehensiveness of reporting, certain discrepancies exist among these companies in the content of their disclosures. Specifically, pharmaceutical companies beat the averages on multiple key CSR topics. However, while disclosures on mature areas such as environment and labor relations show some level of standardization, those focusing particularly on sensitive areas such as human rights and supply chain are far from being standardized. The authors also find that CSR reports that do not include all of SASB’s material topics are just as comprehensive as those that do. A detailed analysis of US and non-US companies separately further revealed that this result is valid for both groups of companies.Research limitations/implicationsConsidering the voluntary nature of CSR reporting, pharmaceutical companies still resort to selective disclosure techniques to highlight their achievements in areas where they feel more confident while leaving out others that can have potential negative consequences on the company. These results underscore the evolving nature of CSR reporting in the pharmaceutical industry and call for more attention and further investigation from managers and researchers alike.Originality/valueThe originality and value of the research show that despite its rapid growth and wide recognition by different segments of society and business as an effective and promising concept, CSR reporting has not yet reached a point where its expected benefits are realized. Focusing on the disclosure side of the story, this paper tries to identify the extent to which the pharmaceutical industry appropriately addresses increasing societal demand for enhanced transparency on its sustainable business policies and practices. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Sustainability Accounting, Management and Policy Journal Emerald Publishing

Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry

Download PDF
32 pages

Loading next page...
 
/lp/emerald-publishing/consistencies-and-discrepancies-in-corporate-social-responsibility-JUkyx1WgYN
Publisher
Emerald Publishing
Copyright
© Emerald Publishing Limited
ISSN
2040-8021
DOI
10.1108/sampj-03-2018-0094
Publisher site
See Article on Publisher Site

Abstract

This paper aims to examine the consistencies and discrepancies in corporate social responsibility (CSR) reporting by analyzing the CSR reports of pharmaceutical companies. Despite the major role pharmaceutical companies play in the CSR field, our knowledge of the extent to which their disclosures provide comprehensive, material, credible and accurate information on their actual performances is limited because of a lack of sufficient literature on the CSR reporting practices of pharmaceutical companies.Design/methodology/approachThe authors present a literature review that serves as the basis to develop the two key research questions: Do pharmaceutical companies publish comprehensive CSR reports? Are company reports that cover more material issues more comprehensive? Using the information on material CSR topics provided by the Sustainability Accounting Standards Board (SASB) and CSR reporting quality scores by the CSR-Sustainability Monitor®, the authors analyzed the CSR reports of the world’s 15 leading pharmaceutical companies. A total of 11 material topics from SASB were mapped onto the corresponding contextual elements in the CSR-Sustainability Monitor. The Monitor evaluates CSR reports published by the world’s largest companies in terms of the degree of transparency and external verification of reporting.FindingsThe analyses revealed that while the pharmaceutical industry outperforms other industries in terms of the overall comprehensiveness of reporting, certain discrepancies exist among these companies in the content of their disclosures. Specifically, pharmaceutical companies beat the averages on multiple key CSR topics. However, while disclosures on mature areas such as environment and labor relations show some level of standardization, those focusing particularly on sensitive areas such as human rights and supply chain are far from being standardized. The authors also find that CSR reports that do not include all of SASB’s material topics are just as comprehensive as those that do. A detailed analysis of US and non-US companies separately further revealed that this result is valid for both groups of companies.Research limitations/implicationsConsidering the voluntary nature of CSR reporting, pharmaceutical companies still resort to selective disclosure techniques to highlight their achievements in areas where they feel more confident while leaving out others that can have potential negative consequences on the company. These results underscore the evolving nature of CSR reporting in the pharmaceutical industry and call for more attention and further investigation from managers and researchers alike.Originality/valueThe originality and value of the research show that despite its rapid growth and wide recognition by different segments of society and business as an effective and promising concept, CSR reporting has not yet reached a point where its expected benefits are realized. Focusing on the disclosure side of the story, this paper tries to identify the extent to which the pharmaceutical industry appropriately addresses increasing societal demand for enhanced transparency on its sustainable business policies and practices.

Journal

Sustainability Accounting, Management and Policy Journal – Emerald Publishing

Published: Jun 6, 2019

Keywords: Pharmaceutical industry; Sustainability; Corporate Social Responsibility (CSR); CSR disclosure; CSR-Sustainability Monitor; Sustainable Accounting Standards Board (SASB)

References

  • Abbott global citizenship report 2014
  • The trend of integrated reporting practice in South Africa: ceremonial or substantive?
    Ahmed Haji, A.; Anifowose, M.
  • The future of corporate sustainability reporting
    Ballou, B.; Heitger, D.L.; Landes, C.E.
  • Annual report 2013 augmented version
  • Impression management: developing and illustrating a scheme of analysis for narrative disclosures: a methodological note
    Brennan, N.M.; Guillamon-Saorin, E.; Pierce, A.
  • The public disclosure of environmental performance information – a dual test of media agenda setting theory and legitimacy theory
    Brown, N.; Deegan, C.
  • Corporate social responsibility reporting: a content analysis in family and non-family firms
    Campopiano, G.; De Massis, A.
  • The corporate social responsibility of pharmaceutical product recalls: an empirical examination of US and UK markets
    Cheah, E.T.; Chan, W.L.; Chieng, C.L.L.
  • The role of environmental disclosures as tools of legitimacy: a research note
    Cho, C.H.; Patten, D.M.
  • Enhancing the credibility of reporting on corporate social responsibility in Europe
    De Beelde, I.; Tuybens, S.
  • Voluntary nonfinancial disclosure and the cost of equity Capital: the initiation of corporate social responsibility reporting
    Dhaliwal, D.S.; Li, O.Z.; Tsang, A.; Yang, Y.G.
  • Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms
    Droppert, H.; Bennett, S.
  • The need for sector-specific materiality and sustainability reporting standards
    Eccles, R.G.; Krzus, M.P.; Rogers, J.; Serafeim, G.
  • 2015 integrated report
  • Strengthening corporate social responsibility in the pharmaceutical industry
    Esteban, D.
  • Effect of stakeholders’ pressure on transparency of sustainability reports within the GRI framework
    Fernandez-Feijoo, B.; Romero, S.; Ruiz, S.
  • Stakeholder theory of the modern corporation
    Freeman, R.E.; Donaldson, T.; Werhane, P.
  • The social responsibility of business is to increase its profits
    Friedman, M.
  • Determinants of voluntary CSR disclosure: empirical evidence from Germany
    Gamerschlag, R.; Möller, K.; Verbeeten, F.
  • Corporate responsibility report 2013
  • Responsible business supplement 2015
  • Earnings and impression management in financial reports: the case of CEO changes
    Godfrey, J.; Mather, P.; Ramsay, A.
  • Flash report: 81 per cent of S&P 500 companies published sustainability reports in 2015 [press release]
  • A re-evaluation of social, environmental and sustainability accounting
    Gray, R.
  • Environmental and social accounting and reporting
    Gray, R.; Collison, D.; Bebbington, J.
  • Corporate social and environmental reporting: a review of the literature and a longitudinal study of UK disclosure
    Gray, R.; Kouhy, R.; Lavers, S.
  • Industry payments to physicians for opioid products, 2013–2015
    Hadland, S.; Krieger, M.; Marshall, L.
  • On legitimacy, legitimation, and organizations: a critical review and integrative theoretical model
    Hybels, R.C.
  • Corporate sustainability: first evidence on materiality
    Khan, M.; Serafeim, G.; Yoon, A.
  • Trends in sustainability reporting by the fortune global 250
    Kolk, A.
  • Pharmaceuticals in the environment: scientific evidence of risks and its regulation
    Küster, A.; Adler, N.
  • A review of the theories of corporate social responsibility: its evolutionary path and the road ahead
    Lee, M.D.P.
  • Benchmarking and transparency: Incentives for the pharmaceutical industry’s corporate social responsibility
    Lee, M.; Kohler, J.
  • The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation
    Leisinger, K.M.
  • Corporate disclosure of environmental liability information: theory and evidence
    Li, Y.; Richardson, G.D.; Thornton, D.B.
  • Should pharmaceutical companies engage in corporate social responsibility?
    Min, M.; Desmoulins-Lebeault, F.; Esposito, M.
  • Opioid overdose crisis
  • 2013 Corporate responsibility performance report
  • 2015 Corporate responsibility performance report
  • Strategic responses to institutional processes
    Oliver, C.
  • Corporate social responsibility (CSR): models and theories in stakeholder dialogue
    O’Riordan, L.; Fairbrass, J.
  • The relation between environmental performance and environmental disclosure: a research note
    Patten, D.M.
  • Building a portrait of corporate social reporting
    Perrini, F.
  • Discretionary compliance with mandatory environmental disclosures: Evidence from SEC filings
    Peters, G.F.; Romi, A.M.
  • Corporations and the environment: greening or preening?
    Sethi, S.P.
  • Building corporate reputation through corporate social responsibility (CSR) reports: the case of extractive industries
    Sethi, S.P.; Martell, T.F.; Demir, M.
  • An evaluation of the quality of corporate social responsibility reports by some of the world’s largest financial institutions
    Sethi, S.P.; Martell, T.F.; Demir, M.
  • Enhancing the role and effectiveness of corporate social responsibility (CSR) reports: the missing element of content verification and integrity assurance
    Sethi, S.P.; Martell, T.F.; Demir, M.
  • Enhancing the quality of reporting in corporate social responsibility guidance documents: the roles of ISO 26000, global reporting initiative and CSR-sustainability monitor
    Sethi, S.P.; Rovenpor, J.L.; Demir, M.
  • Integrated reporting in South Africa: some initial evidence
    Setia, N.; Abhayawansa, S.; Joshi, M.; Huynh, A.V.
  • An approach to incorporating societal preferences in developing corporate action strategies
    Shocker, A.D.; Sethi, S.P.
  • Corporate social responsibility: whether or how?
    Smith, N.C.
  • Social and environmental accounting as symbolic and substantive means of legitimation: the case of HIV/AIDS reporting in South Africa
    Soobaroyen, T.; Ntim, C.G.
  • Managing legitimacy: strategic and institutional approaches
    Suchman, M.C.
  • Do different industries report corporate social responsibility differently? An investigation through the lens of stakeholder theory
    Sweeney, L.; Coughlan, J.
  • Indicators for measuring environmental sustainability: a case study of the pharmaceutical industry
    Veleva, V.; Hart, M.; Greiner, T.; Crumbley, C.
  • CSR disclosure in response to major airline accidents: a legitimacy-based exploration
    Vourvachis, P.; Woodward, T.; Woodward, D.G.; Patten, D.M.
  • The harm of symbolic actions and green-washing: Corporate actions and communications on environmental performance and their financial implications
    Walker, K.; Wan, F.
  • Integrated and decoupled corporate social performance: Management commitments, external pressures, and corporate ethics practices
    Weaver, G.R.; Trevino, L.K.; Cochran, P.L.
  • CSR-sustainability monitor report on the scope and quality of CSR reports from the world’s largest companies
  • CSR-sustainability monitor report on the scope and quality of CSR reports from the world’s largest companies
  • The symbolic management of stockholders: corporate governance reforms and shareholder reactions
    Westphal, J.D.; Zajac, E.J.